PT-141 Peptide Therapy
Understanding PT-141 (Bremelanotide)
PT-141, also known as bremelanotide, is a synthetic peptide studied as a melanocortin receptor agonist.
Important Information
PT-141 is not FDA-approved and is not offered at Cienega Medical. This page is for general education only and is not medical advice.
What Is PT-141?
PT-141 (bremelanotide) is a synthetic peptide that belongs to the melanocortin class and acts on melanocortin receptors in the central nervous system. One formulation of bremelanotide is marketed under the brand name Vyleesi, which received U.S. FDA approval in 2019 as a prescription product. Outside of that specific FDA-approved branded product, raw or compounded PT-141 peptide is generally categorized as a research peptide and is not an FDA-approved drug in those forms. This page is provided for general educational reference only.
FAQ
Click on a question to see more
-
What is PT-141?
PT-141, also called bremelanotide, is a synthetic peptide in the melanocortin family that interacts with melanocortin receptors. It has been the subject of scientific and clinical research, and one branded formulation has been reviewed by regulators.
-
Is PT-141 FDA-approved?
A specific branded formulation of bremelanotide (Vyleesi) received FDA approval in 2019 as a prescription product. PT-141 sold as a raw or compounded research peptide is not an FDA-approved drug and is generally classified as a research compound.
-
Does Cienega Medical offer PT-141?
No. PT-141 is not offered at Cienega Medical. This page exists solely for general educational reference.
Cared for by our 15-person Los Angeles medical team. Meet your provider →